{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:22:56Z","timestamp":1793798576378,"version":"4.6.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder that results in the accumulation of glycosaminoglycans causing progressive multi-organ dysfunction. Its clinical spectrum is very broad and varies from the severe Hurler phenotype (MPS I-H) which is characterized by early and progressive central nervous system (CNS) involvement to the attenuated Scheie phenotype (MPS I-S) with no CNS involvement. Indication, optimal timing, safety and efficacy of the two available treatment options for MPS I, enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), are subject to continuing debate. A European consensus procedure was organized to reach consensus about the use of these two treatment strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A panel of specialists, including 8 specialists for metabolic disorders and 7 bone marrow transplant physicians, all with acknowledged expertise in MPS I, participated in a modified Delphi process to develop consensus-based statements on MPS I treatment. Fifteen MPS I case histories were used to initiate the discussion and to anchor decisions around either treatment mode. Before and at the meeting all experts gave their opinion on the cases (YES\/NO transplantation) and reasons for their decisions were collected. A set of draft statements on MPS I treatment options composed by a planning committee were discussed and revised during the meeting until full consensus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Full consensus was reached on several important issues, including the following: 1) The preferred treatment for patients with MPS I-H diagnosed before age 2.5 yrs is HSCT; 2) In individual patients with an intermediate phenotype HSCT may be considered if there is a suitable donor. However, there are no data on efficacy of HSCT in patients with this phenotype; 3) All MPS I patients including those who have not been transplanted or whose graft has failed may benefit significantly from ERT; 4) ERT should be started at diagnosis and may be of value in patients awaiting HSCT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This multidisciplinary consensus procedure yielded consensus on the main issues related to therapeutic choices and research for MPS I. This is an important step towards an international, collaborative approach, the only way to obtain useful evidence in rare diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1750-1172-6-55","type":"journal-article","created":{"date-parts":[[2011,8,10]],"date-time":"2011-08-10T18:22:33Z","timestamp":1313000553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":202,"title":["Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure"],"prefix":"10.1186","volume":"6","author":[{"given":"Minke H","family":"de Ru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anibh M","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna H","family":"van der Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar","family":"Mahlaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Offringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"O'Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Rovelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Walter","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassili","family":"Valayannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Vellodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits A","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,10]]},"reference":[{"key":"315_CR1","volume-title":"The Online Metabolic and Molecular Bases of Inherited Disease","author":"EF Neufeld","year":"2007","unstructured":"Neufeld EF, Muenzer J: The mucopolysaccharidoses. The Online Metabolic and Molecular Bases of Inherited Disease volume chapter 136. Edited by: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A. New York: McGraw-Hill; 2007."},{"key":"315_CR2","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","volume":"28","author":"F Baehner","year":"2005","unstructured":"Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, Kohlsch\u00fctter A, Kampmann C, Beck M: Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis. 2005, 28: 1011-1017. 10.1007\/s10545-005-0112-z.","journal-title":"J Inherit Metab Dis"},{"key":"315_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/adc.2007.135772","volume":"94","author":"AM Murphy","year":"2009","unstructured":"Murphy AM, Lambert D, Treacy EP, O'Meara A, Lynch SA: Incidence and prevalence of MPS I in the Irish Republic. Arch Dis Child. 2009, 94: 52-54. 10.1136\/adc.2007.135772.","journal-title":"Arch Dis Child"},{"key":"315_CR4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.GIM.0000078027.83236.49","volume":"5","author":"NJ Terlato","year":"2003","unstructured":"Terlato NJ, Cox GF: Can mucopolysaccharidosis type I disease severity be predicted on a patient's genotype? A comprehensive review of the literature. Genet Med. 2003, 5: 286-294. 10.1097\/01.GIM.0000078027.83236.49.","journal-title":"Genet Med"},{"key":"315_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","volume":"91","author":"GM Pastores","year":"2007","unstructured":"Pastores GM, Arn P, Beck M, Clarke JT, Guffon N, Kaplan P, Muenzer J, Norato DY, Shapiro E, Thomas J, Viskochil D, Wraith JE: The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab. 2007, 91: 37-47. 10.1016\/j.ymgme.2007.01.011.","journal-title":"Mol Genet Metab"},{"key":"315_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1542\/peds.2008-0416","volume":"123","author":"J Muenzer","year":"2009","unstructured":"Muenzer J, Wraith JE, Clarke LA, International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I: Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009, 123: 19-29. 10.1542\/peds.2008-0416.","journal-title":"Pediatrics"},{"key":"315_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, Izykowski B, Philips J, Doreshow R, Walot I, Hoft R, Neufeld EF: Enzyme replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001, 344: 182-188. 10.1056\/NEJM200101183440304.","journal-title":"N Engl J Med"},{"key":"315_CR8","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Swiedler SJ, Kakkis ED, Braakman T, Chadbourne E, Walton-Bowen K, Cox GF: Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alfa-l-iduronidase (laronidase). J Pediatr. 2004, 144: 581-588. 10.1016\/j.jpeds.2004.01.046.","journal-title":"J Pediatr"},{"key":"315_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, Okazaki S, Huff K, Cox GF, Swiedler SJ, Kakkis ED: A follow-op study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007, 90: 171-180. 10.1016\/j.ymgme.2006.08.007.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"315_CR10","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, Kakkis ED, Guffon N: Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alfa-l-iduronidase (laronidase). Paediatrics. 2007, 120 (1): e37-46. 10.1542\/peds.2006-2156.","journal-title":"Paediatrics"},{"key":"315_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF: Long-term efficacy and safety of laronidase in the treatment of Mucopolysaccharidosis I. Pediatrics. 2009, 123: 229-240. 10.1542\/peds.2007-3847.","journal-title":"Pediatrics"},{"key":"315_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10545-010-9059-9","volume":"33","author":"A Tylki-Szymanska","year":"2010","unstructured":"Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska B: Efficacy of recombinant human \u03b1-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis. 2010, 33: 151-157. 10.1007\/s10545-010-9059-9.","journal-title":"J Inherit Metab Dis"},{"key":"315_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/bmme.1996.0044","volume":"58","author":"ED Kakkis","year":"1996","unstructured":"Kakkis ED, McEntee MF, Schmidtchen A, Neufeld EF, Ward DA, Gompf RE, Kania S, Bedolla C, Chien SL, Shull RM: Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med. 1996, 58: 156-167. 10.1006\/bmme.1996.0044.","journal-title":"Biochem Mol Med"},{"key":"315_CR14","doi-asserted-by":"publisher","first-page":"60ra89","DOI":"10.1126\/scitranslmed.3001380","volume":"2","author":"AD Dierenfeld","year":"2010","unstructured":"Dierenfeld AD, McEntee MF, Vogler CA, Vite CH, Chen AH, Passage M, Le S, Shah S, Jens JK, Snella EM, Kline KL, Parkes JD, Ware WA, Moran LE, Fales-Williams AJ, Wengert JA, Whitley RD, Betts DM, Boal AM, Riedesel EA, Gross W, Ellinwood NM, Dickson PI: Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med. 2010, 2: 60ra89.","journal-title":"Sci Transl Med"},{"key":"315_CR15","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood.V87.11.4894.bloodjournal87114894","volume":"87","author":"C Peters","year":"1996","unstructured":"Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, Henslee-Downey J, Trigg ME, Cowan MJ, Sanders J, Bunin N, Weinstein H, Lenarsky C, Falk P, Harris R, Bowen T, Williams TE, Grayson GH, Warkentin P, Sender L, Cool VA, Crittenden M, Packman S, Kaplan P, Lockman LA, Anderson J, Krivit W, Dusenbery K, Wagner J: Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 1996, 87: 4894-4902.","journal-title":"Blood"},{"key":"315_CR16","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.V91.7.2601","volume":"91","author":"C Peters","year":"1998","unstructured":"Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ, Saunders EF, deAlarcon PA, Twist C, Nachman JB, Hale GA, Harris RE, Rozans MK, Kurtzberg J, Grayson GH, Williams TE, Lenarsky C, Wagner JE, Krivit W: Hurler Syndrome: II. Outcome of HLA-Genotypically Identical Sibling and HLA-Haploidentical Related Donor Bone Marrow Transplantation in Fifty-Four Children. Blood. 1998, 91: 2601-2608.","journal-title":"Blood"},{"key":"315_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pcl.2009.11.004","volume":"57","author":"JJ Boelens","year":"2010","unstructured":"Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C: Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am. 2010, 57: 123-45. 10.1016\/j.pcl.2009.11.004.","journal-title":"Pediatr Clin North Am"},{"key":"315_CR18","volume-title":"The RAND UCLA Appropriateness Method User's Manual","author":"K Fitch","year":"2001","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, Van het Loo M, McDonnell J, Vader JP, Kahan JP: The RAND UCLA Appropriateness Method User's Manual. Santa Monica (CA): Rand Corp; 2001."},{"key":"315_CR19","volume-title":"The Delphi method: techniques and applications","author":"H Linstone","year":"1975","unstructured":"Linstone H, Turof M: The Delphi method: techniques and applications. Reading, MA: Addison-Wesley; 1975."},{"key":"315_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ymgme.2007.11.002","volume":"93","author":"GL Arnold","year":"2008","unstructured":"Arnold GL, Koeberl DD, Matern D, Barshop B, Braverman N, Burton B, Cederbaum S, Fiegenbaum A, Garganta C, Gibson J, Goodman SI, Harding C, Kahler S, Kronn D, Longo N: A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab. 2008, 93: 363-370. 10.1016\/j.ymgme.2007.11.002.","journal-title":"Mol Genet Metab"},{"key":"315_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymgme.2008.09.008","volume":"96","author":"GL Arnold","year":"2009","unstructured":"Arnold GL, Van Hove J, Freedenberg D, Strauss A, Longo N, Burton B, Garganta C, Ficicioglu C, Cederbaum S, Harding C, Boles RG, Matern D, Chakraborty P, Feigenbaum A: A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab. 2009, 96: 85-90. 10.1016\/j.ymgme.2008.09.008.","journal-title":"Mol Genet Metab"},{"key":"315_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1037\/h0026256","volume":"70","author":"J Cohen","year":"1968","unstructured":"Cohen J: Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychological Bulletin. 1968, 70: 213-220.","journal-title":"Psychological Bulletin"},{"key":"315_CR23","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG: Practical statistics for medical research. London: Chapman & Hall; 1991."},{"key":"315_CR24","first-page":"973","volume":"53","author":"HS Scott","year":"1993","unstructured":"Scott HS, Litjens T, Nelson PV, Thompson PR, Brooks DA, Hopwood JJ, Morris CP: Identification of mutations in the a-L-iduronidase gene (IDUA) that cause Hurler and Scheie syndromes. Am J Hum Genet. 1993, 53: 973-986.","journal-title":"Am J Hum Genet"},{"key":"315_CR25","doi-asserted-by":"publisher","first-page":"E2189","DOI":"10.1002\/humu.21479","volume":"32","author":"F Bertola","year":"2011","unstructured":"Bertola F, Filocamo M, Casati G, Mort M, Rosano C, Tylki-Szymanska A, T\u00fcys\u00fcz B, Gabrielli O, Grossi S, Scarpa M, Parenti G, Antuzzi D, Dalmau J, Rocco MD, Vici CD, Okur I, Rosell J, Rovelli A, Furlan F, Rigoldi M, Biondi A, Cooper DN, Parini R: IDUA mutational profiling of a cohort of 102 European patients with Mucopolysaccharidosis type I: identification and characterization of 35 novel \u03b1-L-iduronidase (IDUA) alleles. Hum Mutat. 2011, 32: E2189-E2210. 10.1002\/humu.21479.","journal-title":"Hum Mutat"},{"key":"315_CR26","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/hmg\/2.9.1471","volume":"2","author":"HS Scott","year":"1993","unstructured":"Scott HS, Nelson PV, Litjens T, Hopwood JJ, Morris CP: Multiple polymorphisms within the alpha-L-iduronidase gene (IDUA): implications for a role in modification of MPS-I disease phenotype. Hum Mol Genet. 1993, 2: 1471-1473. 10.1093\/hmg\/2.9.1471.","journal-title":"Hum Mol Genet"},{"key":"315_CR27","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s10545-005-0258-8","volume":"29","author":"JJ Boelens","year":"2006","unstructured":"Boelens JJ: Trends in haematopoietic cell transplantation for inborn errors of metabolism. J Inherit Metab Dis. 2006, 29: 413-420. 10.1007\/s10545-005-0258-8.","journal-title":"J Inherit Metab Dis"},{"key":"315_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.bmt.1705718","volume":"40","author":"JJ Boelens","year":"2007","unstructured":"Boelens JJ, Wynn RF, O'Meara A, Veys P, Bertrand Y, Souillet G, Wraith JE, Fischer A, Cavazzana-Calvo M, Sykora KW, Sedlacek P, Rovelli A, Uiterwaal CS, Wulffraat N: Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant. 2007, 40: 225-233. 10.1038\/sj.bmt.1705718.","journal-title":"Bone Marrow Transplant"},{"key":"315_CR29","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.bbmt.2009.01.020","volume":"15","author":"JJ Boelens","year":"2009","unstructured":"Boelens JJ, Rocha V, Aldenhoven M, Wynn R, O'Meara A, Michel G, Ionescu I, Parikh S, Prasad VK, Szabolcs P, Escolar M, Gluckman E, Cavazzana-Calvo M, Kurtzberg J, EUROCORD, Inborn error Working Party of EBMT and Duke University: Risk Factor Analysis of Outcomes after Unrelated Cord Blood Transplantation in Patients with Hurler Syndrome. Biol Blood Marrow Transplant. 2009, 15: 618-625. 10.1016\/j.bbmt.2009.01.020.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 2","key":"315_CR30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.bbmt.2009.12.091","volume":"16","author":"JJ Boelens","year":"2010","unstructured":"Boelens JJ, Aldenhoven M, Purtill D, Eapen M, DeForr T, Wynn R, Cavazanna-Calvo M, Tolar J, Prasad VK, Escolar M, Gluckman E, Orchard P, Veys P, Kurtzberg J, Rocha V: Outcomes of transplantation using a various cell source in children with Hurlers syndrome after myelo-ablative conditioning. An Eurocord-EBMT-CIBMTR collaborative study. Biol Blood Marrow Transplant. 2010, 16 (Suppl 2): 180-181.","journal-title":"Biol Blood Marrow Transplant"},{"key":"315_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1080\/08035250510031584","volume":"94","author":"S Vijay","year":"2005","unstructured":"Vijay S, Wraith JE: Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta P\u00e6diatrica. 2005, 94: 872-877.","journal-title":"Acta P\u00e6diatrica"},{"key":"315_CR32","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2010","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV: Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010, 125: e183-e187. 10.1542\/peds.2009-1728.","journal-title":"Pediatrics"},{"key":"315_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.GIM.0000154299.22120.6A","volume":"7","author":"SS Grewal","year":"2005","unstructured":"Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C: Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005, 7: 143-146. 10.1097\/01.GIM.0000154299.22120.6A.","journal-title":"Genet Med"},{"key":"315_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.bmt.1705401","volume":"38","author":"J Cox-Brinkman","year":"2006","unstructured":"Cox-Brinkman J, Boelens JJ, Wraith JE, O'meara A, Veys P, Wijburg FA, Wulffraat N, Wynn RF: Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndrome. Bone Marrow Transplant. 2006, 38: 17-21. 10.1038\/sj.bmt.1705401.","journal-title":"Bone Marrow Transplant"},{"key":"315_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","volume":"41","author":"J Tolar","year":"2008","unstructured":"Tolar J, Grewal SS, Bjoraker KJ, Whitley CB, Shapiro EG, Charnas L, Orchard PJ: Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplantation. 2008, 41: 531-535. 10.1038\/sj.bmt.1705934.","journal-title":"Bone Marrow Transplantation"},{"key":"315_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jpeds.2008.07.004","volume":"154","author":"RF Wynn","year":"2009","unstructured":"Wynn RF, Mercer J, Page J, Carr TF, Jones S, Wraith JE: Use of enzyme replacement therapy (Laronidase) before hematopoietic stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients. J Pediatr. 2009, 154: 135-139. 10.1016\/j.jpeds.2008.07.004.","journal-title":"J Pediatr"},{"key":"315_CR37","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1373\/clinchem.2008.115410","volume":"54","author":"S Blanchard","year":"2008","unstructured":"Blanchard S, Sadilek M, Scott CR, Turecek F, Gelb MH: Tandem mass spectrometry for the direct assay of lysosomal enzymes in dried blood spots: application to screening newborns for mucopolysaccharidosis I. Clin Chem. 2008, 54: 2067-70. 10.1373\/clinchem.2008.115410.","journal-title":"Clin Chem"},{"key":"315_CR38","doi-asserted-by":"publisher","first-page":"e1242","DOI":"10.1542\/peds.2009-2843","volume":"126","author":"V Valayannopoulos","year":"2010","unstructured":"Valayannopoulos V, de Blic J, Mahlaoui N, Stos B, Jaubert F, Bonnet D, Fischer A, de Lonlay P: Laronidase for cardiopulmonary disease in Hurler syndrome 12 years after bone marrow transplantation. Pediatrics. 2010, 126: e1242-1247. 10.1542\/peds.2009-2843.","journal-title":"Pediatrics"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1750-1172-6-55.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:48:09Z","timestamp":1630511289000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/1750-1172-6-55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,10]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1186\/1750-1172-6-55","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,10]]},"assertion":[{"value":"25 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"55"}}